| Heading: |
Pregnancy: Drugs |
| Question ID: |
1813001 |
| UIN: |
60035 |
| House: |
Commons |
| Date tabled: |
2025-06-16 |
| Asking Member ID: |
1506 |
| Asking Member display name: |
Andrew Gwynne
|
| Asking Member handle: |
GwynneMP
|
| Asking Member Twitter reference: |
@GwynneMP
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the medicines licensing process for novel medications in being able to detect potential teratogenicity prior to the medicine being made available |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-20 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
The Medicines and Healthcare products Regulatory Agency (MHRA) is a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), which uses internationally standardised guidelines and principles ... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |